Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.
Status:
Not yet recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
IIBR-100 (VSV-ΔG) is a self-propagating live virus vaccine that contains the spike protein of
the Wuhan wild-type SARS-CoV-2 virus. Preclinical and phase 1/2 trials have demonstrated no
safety signals of concern and have further demonstrated immunologic response that
approximates the response seen in convalescent individuals. The purpose of this phase 2b/3
trial is to document the non-inferiority of IIBR-100 vs. an already-approved vaccine for
COVID-19.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
NeuroRx, Inc.
Collaborators:
Brilife Georgia Cromos Iqvia Pty Ltd Israel Institute for Biological Research